… , a primary care doctor and researcher at Harvard Medical School and Brigham … he said pharmaceutical companies were “getting away with murder.” Drug companies were … of brand-name drugs — such as Remicade and Stelara, which made up …

… Medicine, about icotrokinra’s mechanism of action, promising clinical trial … 39;re studying it against Stelara, or ustekinumab. Dermatology … choose to access this drug or others that may … icotrokinra US FDA approval aiming to revolutionize treatment paradigm …

… will become the predominant drug that’s used. It … understand that there’s the Medicare Part D redesign. But … to be launching generic STELARA — biosimilar STELARA in Europe in quarter … disconnect your lines. Follow Teva Pharmaceutical Industries Ltd (NYSE:TEVA) …

… in the medical industries, where the development of new drugs and devices … span pharmaceuticals – where it has market-leading drugs like Darzalex, Stelara and Xarelto … devices. Just one other applicant – medical device specialist Medtronic – exceeded the …

… based generics and innovative medicines hybrid has “absorbed … products—including its lead drug Austedo—are manufactured locally … national security implications of pharmaceutical imports could influence the … Johnson & Johnson’s Stelara. Teva is planning two …

… drug substances. It is based at “a major pharmaceutical … cancer and autoimmune disease treatments—for several years,” … reference drugs like Johnson & Johnson’s Remicade and Stelara, … repeatedly threatened to impose pharmaceutical import tariffs, sometimes …

… drugs when they pick them up from the pharmacy. Medicare and Medicaid … like Humira and Stelara, which treat everything from … markets," the Pharmaceutical Research and Manufacturers of … devastating illnesses, attacked vaccines and fluoride, and signed …

… surge in innovative drug approvals, particularly from small pharmaceutical companies, many of … , with the FDA granting approval for the first biosimilar of Stelara, Wezlana … patient access to cost-effective treatments and increase the utilization of …

… authorisation for the medicinal product Usrenty, intended for the treatment of adults … to product Stelara.  Plaque psoriasis Usrenty is indicated for the treatment of … -biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate …

… disease drug manufacturers respond to accelerating market disruption across the pharmaceutical … UnitedHealthcare’s formulary status for Stelara® illustrates, biopharma companies must … maximize therapeutic opportunities for the treatment of orphan and rare …